SS-31: The Peptide That Targets Mitochondria From the Inside
Most antioxidants work by mopping up free radicals after they’ve already been produced. SS-31 takes a fundamentally different approach — it goes directly to where those free radicals are generated, binds to a lipid most researchers have never heard of, and stabilizes the machinery of energy production itself.
In September 2025, the FDA granted accelerated approval to elamipretide (the pharmaceutical name for SS-31) for the treatment of Barth syndrome, a rare mitochondrial disorder. That approval validated decades of research into a four-amino-acid peptide that may represent an entirely new category of mitochondrial medicine.
Here’s what makes it interesting — and why researchers across multiple fields are paying attention.
Cardiolipin: The Lipid You Should Know About
Every cell in your body runs on mitochondria. And every mitochondrion depends on a phospholipid called cardiolipin to function properly.
Cardiolipin lives exclusively in the inner mitochondrial membrane — nowhere else in the cell. It performs several critical jobs: it anchors the respiratory chain complexes that produce ATP, it maintains the tightly folded cristae structure that maximizes energy output, and it keeps cytochrome c (a key electron carrier) functioning as an electron shuttle rather than as a destructive peroxidase enzyme.
When cardiolipin is damaged — by oxidative stress, aging, or genetic mutations — the consequences cascade. Respiratory complexes disassemble. Electron transfer becomes inefficient. Electrons leak from the chain and react with oxygen to form superoxide. The mitochondria produce less energy and more waste. Cells dependent on high energy output — heart muscle, skeletal muscle, neurons, kidneys — feel it first.
Barth syndrome, the disease that brought SS-31 to FDA approval, is caused by mutations in the tafazzin gene responsible for cardiolipin remodeling. Patients can’t maintain healthy cardiolipin, and their mitochondria slowly fail. It’s the clearest example of what goes wrong when this one lipid breaks down — but the same process, at a slower rate, appears in aging tissue throughout the body.
How SS-31 Works
SS-31 is a synthetic tetrapeptide: four amino acids in the sequence D-Arg–Dmt–Lys–Phe-NH₂ (where Dmt is 2′,6′-dimethyltyrosine). That sequence gives it two unusual properties.
First, the alternating aromatic-cationic pattern allows it to cross cell membranes without needing a transporter or energy input. Within minutes of exposure, SS-31 concentrates more than 1,000-fold inside mitochondria — driven by the strong negative charge of the inner membrane.
Second, once there, it binds directly to cardiolipin through a combination of electrostatic attraction (the peptide carries a +3 charge at physiological pH) and hydrophobic contacts between its aromatic residues and cardiolipin’s acyl chains.
That binding does several things simultaneously:
- Stabilizes respiratory supercomplexes. Complexes I, III, and IV assemble into supercomplexes on cardiolipin scaffolds. SS-31 helps maintain these assemblies, keeping electron transfer efficient and reducing the electron leak that produces superoxide.
- Preserves cytochrome c function. Damaged cardiolipin converts cytochrome c from an electron carrier into a peroxidase that generates more oxidative damage. SS-31 prevents this conversion — a mechanism fundamentally different from scavenging free radicals after they form.
- Restores cristae architecture. Research shows SS-31 promotes the curved membrane folds (cristae) where oxidative phosphorylation is most efficient. Flattened or disordered cristae — a hallmark of aged and diseased mitochondria — reorganize toward their functional morphology.
- Improves ADP sensitivity. Healthy mitochondria respond quickly when cells demand energy (signaled by rising ADP levels). SS-31 restores this coupling through interactions with the adenine nucleotide translocator, so ATP production tracks energy demand more closely.
The net result is a mitochondrion that produces more ATP with less oxidative waste — not because free radicals are being neutralized downstream, but because the source of inefficiency has been structurally corrected.
What the Research Shows
SS-31 has been investigated across a wide range of research models, consistently demonstrating effects tied to its cardiolipin-stabilizing mechanism.
Cardiac research has been the most extensively studied area. In models of ischemia-reperfusion — where blood flow is interrupted and then restored, causing a burst of mitochondrial oxidative damage — SS-31 preserves mitochondrial membrane potential and reduces infarct size. These findings are directly relevant to the Barth syndrome clinical context, where cardiomyopathy is the primary cause of morbidity.
Skeletal muscle and aging models show some of the most striking results. A 2019 study in aged mice demonstrated that eight days of SS-31 treatment reversed age-related increases in mitochondrial hydrogen peroxide production, restored the redox environment of muscle cells, and improved exercise tolerance — measured as both treadmill endurance and fatigue resistance. The aged mitochondria showed improved ADP sensitivity, meaning they responded to energy demands more like young mitochondria.
Kidney research examines SS-31 in models of acute kidney injury, where proximal tubule cells depend heavily on mitochondrial ATP production. Disrupted cardiolipin organization in these cells leads to tubular damage; SS-31’s cardiolipin stabilization helps preserve tubular function in these models.
Neurological research explores applications in models where mitochondrial dysfunction contributes to neuronal energy failure and synaptic degeneration. A 2025 study published in the International Journal of Molecular Sciences demonstrated neuroprotective effects of SS-31 in both in vitro and in vivo models of spinal cord injury, with improvements attributed to mitochondrial membrane stabilization.
The FDA Approval and What It Means
Elamipretide received accelerated approval from the FDA in September 2025 for Barth syndrome — a condition affecting fewer than 300 people worldwide. The clinical trial, conducted at Johns Hopkins Medicine, showed that patients receiving the drug had improved cardiolipin levels, reported less fatigue, and demonstrated measurable functional improvements.
Walker Burger, a 35-year-old trial participant who has taken elamipretide since 2017, described the change simply: walking a quarter mile to a baseball stadium used to require multiple breaks. Now it doesn’t.
The approval is significant beyond Barth syndrome for two reasons. First, it validates the cardiolipin-targeting mechanism in humans — not just cell cultures and animal models. Second, it opens the door for investigation in more common conditions that share the same underlying mitochondrial pathology: age-related heart failure, chronic kidney disease, neurodegenerative diseases, and the general decline in mitochondrial function that accompanies aging.
Why Researchers Are Interested
Mitochondrial dysfunction isn’t a niche concern. It appears in the pathology of heart disease, kidney disease, neurodegeneration, metabolic syndrome, sarcopenia, and the basic biology of aging itself. Every one of these conditions involves some combination of impaired electron transport, excessive ROS production, and disrupted energy metabolism.
Until SS-31, there was no pharmacological approach that targeted the structural basis of these problems. Antioxidant supplements scavenge free radicals after they’re produced — a strategy that has largely failed in clinical trials for age-related diseases. SS-31 works upstream, at the point where efficient electron transport prevents excessive free radical generation in the first place.
That distinction — prevention of dysfunction versus cleanup after dysfunction — is why a four-amino-acid peptide originally discovered during opioid receptor research has become one of the most actively studied compounds in mitochondrial medicine.
Structural Advantages
Several design features make SS-31 unusually practical as a research compound:
- D-Arginine at position 1 resists aminopeptidase degradation, giving the peptide better metabolic stability than its all-L-amino-acid counterparts.
- C-terminal amidation (Phe-NH₂) blocks carboxypeptidase cleavage and improves membrane interaction.
- Small size (639.80 Da, four residues) allows rapid cell penetration without carrier systems.
- Water solubility — SS-31 reconstitutes readily in bacteriostatic water without requiring acetic acid or pH adjustment.
For laboratory handling, store lyophilized SS-31 at -20°C. Reconstitute with bacteriostatic water by adding solvent slowly along the vial wall and swirling gently. Reconstituted solution is stable at 2-8°C for up to 28 days.
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
- Campbell MD, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281.
- Reid Thompson W, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021;23(3):471-478.
- Russo S, et al. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Sci Rep. 2024;14:13655.
- Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury. Int J Mol Sci. 2025;26(7):3327.
- FDA grants accelerated approval of elamipretide for Barth syndrome. Johns Hopkins Medicine / FDA. September 2025.
All peptides supplied by Chameleon Peptides undergo independent third-party testing by Janoshik Analytical, an ISO/IEC 17025 accredited laboratory, with purity verification by HPLC and identity confirmation by mass spectrometry.
For research use only. Not for human consumption.